Full text is available at the source.
Abstract
Endocrine therapy for hormone receptor-positive breast cancer is associated with adverse metabolic effects.
- Increased fat mass and decreased lean muscle mass are observed in patients undergoing endocrine therapy.
- Insulin resistance may develop as a result of endocrine therapy.
- These metabolic changes could potentially reduce the effectiveness of GLP-1 receptor agonists for weight loss in this patient group.
Simplified